Close Menu

asset acquisition

UK-based Abcam has acquired Oregon-based life science research tool provider Marker Gene Technologies, the latest in a string of asset purchases.

The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.

Abcam said that acquisition will help it build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative.

Psomagen is buying bankrupt microbiome testing firm uBiome's assets, Stat News reports.

The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.

The technology, called PrecisMed, is designed to detect, measure, and assess over 200 medications in a patient's bloodstream from a finger stick.

Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.

The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.

The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.

By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.